Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Accumulated Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other Accumulated Expenses for 13 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 32.93% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 32.93% year-over-year, with the annual reading at $1.5 million for FY2025, 32.93% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $1.5 million at Theravance Biopharma, up from $1.3 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $2.3 million in Q2 2022, with the low at $142000.0 in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $1.4 million, with a median of $1.5 million recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses crashed 92.24% in 2022, then skyrocketed 963.38% in 2023.
  • Over 5 years, Other Accumulated Expenses stood at $1.3 million in 2021, then fell by 12.42% to $1.1 million in 2022, then grew by 8.67% to $1.2 million in 2023, then skyrocketed by 78.4% to $2.2 million in 2024, then plummeted by 32.93% to $1.5 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $1.5 million, $1.3 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.